Back

Adherence to the guideline-directed medical therapy in chronic heart failure: insight from a University Hospital

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in interventional cardiology and pharmacology 2 Cardiovascular Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maryem Assamti

Mohammed VI University Hospital Centre, Oujda (Morocco)

6 More presentations in this session

Presentation thumbnail
Challenging the norm: the use of sublingual nitroglycerin in patients with severe aortic stenosis undergoing cardiac CT
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Age differences in prescribing guideline-directed medical treatment in heart failure with mildly reduced and reduced ejection fraction
Doctor V. Lopes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
Doctor A. Amanova (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Use of SGLT2 inhibitors in real life: predicting left ventricular reverse remodelling.
Doctor V. De Simone (Legnago, IT)
Abstract Slides Video
Presentation thumbnail
Real world registry of use of SGLT2i in patients with HFrEF followed in a non-tertiary hospital.
Mr V. Martinez Mateo (Alcazar de San Juan, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in interventional cardiology and pharmacology 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
thumbnail
Congress Presentation
Optimizing heart failure management: impact of quadruple therapy initiation at discharge following decompensation events in patients with reduced ejection fraction
thumbnail
Congress Presentation
Initiation and titration of prognostic drug therapy during hospitalization for acute decompensation of heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources